Folate study for men starting hormone therapy for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether taking a medicine called trimethoprim, along with standard hormone therapy, can improve treatment for prostate cancer by affecting folate levels in the blood. It may help men who are about to start hormone therapy for advanced prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a diagnosis of prostate cancer that is high-risk, very high-risk, or has spread to other parts of the body.
- You have not had any previous treatment for prostate cancer.
- You are going to start hormone therapy within 4 weeks of joining the study.
- Your blood tests show specific levels of folate, homocysteine, hemoglobin, and kidney function.
- You are willing to avoid supplements or medicines containing folic acid or potassium while on the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This study tests whether a supervised exercise program can help manage side effects like fatigue and muscle loss when starting hormone therapy for prostate cancer. Participation may improve your quality of life during treatment.
This trial tests whether intermittent fasting (alternating between eating and not eating for certain periods) can help men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). It aims to see if fasting during treatment can reduce side effects or improve how well the therapy works.
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.